A technology for creating next-generation multispecific biologics.
The imunexin™ platform enables the development of biologic medicines that can perform more than one therapeutic function within a single molecule.
This is achieved by attaching small engineered protein modules, known as imunexins™, to existing biologic drugs such as antibodies or enzymes.
By adding these modules, conventional single-target medicines can be converted into multispecific therapies capable of interacting with disease biology in more sophisticated ways.
Many serious diseases involve multiple biological pathways rather than a single target.
Multispecific biologics are designed to address several disease mechanisms within a single therapy.
Multispecific drugs are one of the fastest-growing areas of biologic medicine and are attracting increasing interest from global pharmaceutical companies.
The imunexin ™ platform can be applied across multiple biologic formats, including:
This flexibility enables Imunexus to pursue programs across several disease areas including neurology, oncology, rare diseases and regenerative medicine.
The platform supports both internal drug development and strategic partnerships with pharmaceutical companies seeking to enhance existing biologic drugs.
